Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

25 July 2022: Database Analysis

Integrating Network Pharmacology, Molecular Docking, and Experimental Validation to Investigate the Mechanism of (−)-Guaiol Against Lung Adenocarcinoma

Yaoying Zeng 1E* , Yanbin Pan 1B* , Bo Zhang 1C , Yingbin Luo 1D , Jianhui Tian 1AF , Yuli Wang 1CD , Xudong Ju 2BF , Jianchun Wu 1A* , Yan Li 1A*

DOI: 10.12659/MSM.937131

Med Sci Monit 2022; 28:e937131

Figure 8 (A) Cell survival rate was detected by performing a CCK-8 assay. The LUAD cells (A549 and Calu-1) and normal lung cells BEAS-2B cells treated with different concentrations of (−)-Guaiol. IC50 values were 75.7 μM for A549 cells, 92.1 μM for H1299 cells, and 322.3 μM for BEAS-2B cells. Data from 3 independent experiments were represented as means±SD. (B) A549 and Calu-1 were treated with (−)-Guaiol (75 μM) or (−)-Guaiol (75 μM) companied Z-VAD (20μM) for 24 h. ** P<0.01 vs control in A549. # P<0.05 vs (−)-Guaiol in Calu-1. Data from 3 independent experiments were represented as means±SD. (C) A549 and Calu-1 were treated with or without (−)-Guaiol (75 μM) or (−)-Guaiol (75 μM) and Z-VAD (20 μM), and stained with SYTOX Green (100 nM), then observed under a fluorescence microscope.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750